Express Mail Label No. EV 246879855 US Attorney Docket No.: 3951.244-US

Serial No.: 09/528,644, Filed March 20, 2000

REMARKS

Claims 27-33, 36 and 40-65 are now pending.

In response to the election of species requirement, Applicants respectfully elect the species a homolog of Seq ID No 1 wherein the sequence of the homolog is identical to Seq Id No 1 except for two amino acid substitutions where the amino acid substitutions are in the first trefoil domain. In making this election, Applicants note the Examiner's indication that "Upon allowance of a generic claim, applicant will be entitled to consideration of additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141"

(page 3 of 8/11/03 restriction requirement).

The claims readable on the elected species are claims 27-33, 36, 42-44, 48, 50 and 53-

54.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this paper or application.

Respectfully submitted,

Date: December 11, 2003

Richard W. Bork, Reg. No. 36,459

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540

(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE